ACELYRIN is investing in, developing and commercializing life-changing drug therapies. ACELYRIN’s approach is to identify and develop therapeutics through efficient and ongoing collaborations with academia, big-pharma and early-stage start-ups to get the right expertise throughout the entire process. ACELYRIN’s lead candidate is izokibep, a monoclonal antibody mimetic to inhibit  interleukin-17A (IL-17A) with high potency and tissue penetrance. Currently, ACELYRIN is actively investigating the potential of izokibep in diseases with perturbed IL-17A signaling. This includes Phase 2/3 trials for inflammatory diseases of the eye (Uveitis) and skin (Psoriatic Arthritis). 

<p>ACELYRIN is investing in, developing and commercializing life-changing drug therapies. ACELYRIN’s approach is to identify and develop therapeutics through efficient and ongoing collaborations with academia, big-pharma and early-stage start-ups to get the right expertise throughout the entire process. ACELYRIN’s lead candidate is izokibep, a monoclonal antibody mimetic to inhibit  interleukin-17A (IL-17A) with high potency and tissue penetrance. Currently, ACELYRIN is actively investigating the potential of izokibep in diseases with perturbed IL-17A signaling. This includes Phase 2/3 trials for inflammatory diseases of the eye (Uveitis) and skin (Psoriatic Arthritis). </p>


ACELYRIN

Acelyrin shifts from lead candidate despite positive phase 3 results - BioPharma-Reporter.com

After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory - Fierce Biotech

Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha

Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance

 ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors 

Charles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Acelyrin shares tumble after decision to halt izokibep development on failing trial - Seeking Alpha

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Acelyrin sets out massive $540M upsized IPO

What's Going On With ACELYRIN Shares Friday? - Benzinga

Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep - Benzinga

Here's Why We're Watching Acelyrin's (NASDAQ:SLRN) Cash Burn Situation - Yahoo Finance

Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing Therapies - Viridian Therapeutics, Roche, Immunovant, Amgen, Sling Therapeutics, ACELYRIN, Tourmaline Bio - Yahoo Finance

 ACELYRIN, INC. 

 What's Going On With ACELYRIN Shares Friday? 

ACELYRIN to Present Pivotal Phase 2 Data for Breakthrough Thyroid Eye Disease Treatment - StockTitan

Christine Gustafson, who lives with #ThyroidEyeDisease (TED) and serves as the executive director and CEO of TED Community Organization, understands firsthand the impact TED can have on people’s lives. As a member of our TED Advisory Board, she is a dedicated advocate and strong voice for an improved patient experience. Read more below. #TEDAwarenessWeek

Acelyrin’s founding CEO steps down, company scraps earnings call - Endpoints News

Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St

Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data - BioSpace

Acelyrin reels in $250M to fund 3 late-stage trials ...

Acelyrin’s izokibep for hidradenitis suppurativa reveals positive results - PharmaTimes

Today, we are pleased to report financial results and corporate updates from Q3 2024. CEO Mina Kim shares more on the execution of our refocused pipeline strategy and near-term catalysts ahead for ACELYRIN below. More details here. https://lnkd.in/gb5k-2Jk

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - The Manila Times

We invite investors and industry members to join us this Monday, January 6 for a virtual event where we will unveil new phase 2 data and the phase 3 program design for subcutaneous lonigutamab in #ThyroidEyeDisease. We also look forward to welcoming external clinicians Dr. Andrea Kossler and Dr. Prem Subramanian, MD, PhD to share their insights into ongoing unmet needs in TED. Register here to tune in live. https://lnkd.in/eRB7ceFY

ACELYRIN, INC. Advances Key Drug Developments - TipRanks

ACELYRIN Refocuses on Thyroid Eye Disease, Cuts Workforce - TipRanks

 ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis 

ACELYRIN, INC. Appoints Mina Kim as New CEO - TipRanks

ACELYRIN Faces CFO Resignation and Trial Setback - TipRanks

 Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen 

Today, we announced topline results from the Phase 2b/3 trial of izokibep in uveitis. While we are disappointed the study did not meet its primary endpoint, we extend our sincere gratitude to the patients, families, clinical investigators and ACELYRIN team members for the time and effort that was put into this trial. We look forward to continuing our focus on the development of lonigutamab in thyroid eye disease, with initiation of the Phase 3 program on schedule for Q1 2025. Read more here. https://lnkd.in/eAanJZv4

ACELYRIN's Izokibep Trial Fails Primary Endpoint in Uveitis Study, Shifts Focus to Thyroid Eye Disease Program - StockTitan

Acelyrin loses interest in izokibep, lays off 3rd of staff to focus on looming fight for Tepezza's crown - Fierce Biotech

 Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis (NASDAQ:SLRN) 

SLRN stock touches 52-week low at $3.06 amid market challenges - Investing.com

 Stocks to Watch: iBio, Acelyrin 

Acelyrin bins flagship immunology asset after racking up a few too many failures - FirstWord Pharma

 Acelyrin Shares Fall 11%, Programming Error Found in Arthritis Drug Trial 

Acelyrin announces layoffs, strategy shift after late-stage trial results for anti-inflammatory drug - STAT

Acelyrin: Abandoned Programs Do Not Give Confidence (NASDAQ:SLRN) - Seeking Alpha

Acelyrin crew behind first thyroid eye disease medicine builds its potential competitor, with early data to boast - Endpoints News

 Lowey Dannenberg Notifies ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Conta... 

T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com

Geode Capital Management LLC Grows Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Today marks the start of #ThyroidEyeDisease (TED) Awareness Week. TED is a debilitating and painful autoimmune disease affecting more than 100,000 patients in the US that can cause eye bulging, vision change, and in the most serious cases, lead to loss of vision and blindness. At ACELYRIN, we are committed to reshaping the treatment landscape for people living with TED, and we’ve established a world-class scientific and patient advisory board to inform our efforts. Dr. Shoaib Ugradar, MD shares insight into that work below. #TEDAwarenessWeek

Uveitis is a rare condition that causes inflammation in the uvea, the middle layer of the eye. People with #uveitis typically experience swelling and loss of vision. If not treated promptly, uveitis can lead to permanent vision damage.

It's #UveitisAwarenessMonth. Learn more about uveitis from the American Academy of Ophthalmology. https://lnkd.in/dMS_EDva

 Acelyrin Flags CRO Errors in Izokibep Program After Late-Stage Failure 

ACELYRIN Sets Q3 2024 Earnings Call: Immunology Pipeline Updates Coming Nov 13 - StockTitan

 Acelyrin Promotes Atty To CLO, As Legal Chief Becomes CEO 

 Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) 

Pipeline - ACELYRIN

iTeos shares jump on TIGIT update; Acelyrin swaps CEOs - BioPharma Dive

Acelyrin Finance Chief Gil Labrucherie to Exit - MarketWatch

We look forward to hosting a conference call on Wednesday, November 13 to discuss our third quarter 2024 financial results and other corporate updates. Full details here. https://lnkd.in/eVxwdvJG

 After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory 

 Acelyrin, Inc. (SLRN) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Acelyrin, Inc. 

Why Is Acelyrin, Inc. (SLRN) Among the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance

 Acelyrin's founding CEO steps down, company scraps earnings call 

 Wells upgrades Acelyrin to Overweight with shares trading below cash 

 FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and more 

Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff - Pharmaceutical Technology

 Acelryin reports dose sequencing errors in Phase 2/3 study for izokibep 

Acelyrin brings total raised in 1 year past past $500M mark

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - The Manila Times

 Acelyrin (SLRN) Phase 2b/3 trial of izokibep did not meet primary endpoint 

Acelyrin Shares Fall After Halting Development of Eye Disease Treatment - MarketWatch

 Acelyrin provides business and milestone update 

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - The Manila Times

ACELYRIN - ACELYRIN

Cour Pharmaceuticals tabs ex-Acelyrin chief Paul Peloso, MD as medical head - MM+M Online

 Chutes & Ladders—Sanofi CSO steps down 

C-suite changes at Acelyrin could signal reprioritizations in pipeline - BioCentury

 These Stocks Are Moving the Most Today: Zscaler, CrowdStrike, Boeing, Acelyrin, iRobot, and More 

With only a few treatment options available for #uveitis, patients and clinicians need better early and longer-term, disease-modifying treatment of the disease to address its potential complications, including eventual blindness. This #UveitisAwarenessMonth and every month, the ACELYRIN team is proud to be working to potentially improve the standard of care for patients with uveitis. Learn more on our website. https://lnkd.in/e3CGamEw

 Acelyrin jumps 10% on izokibep psoriatic arthritis results 

Chutes & Ladders—Sanofi CSO steps down - Fierce Biotech

 UPDATE: Acelyrin points to CRO error that could explain shocking phase 3 failure 

 ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program 

Acelyrin shifts from main drug, lays off staff - BioPharma Dive

Acelyrin fails late-phase clinical trial months after $540M IPO

 Acelyrin management to meet virtually with Piper Sandler 

 HS dropout as math favors Acelyrin’s TED course with lonigutamab 

Acelyrin spikes on upcoming mid-stage data update on eye disease drug - MSN

Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now? - Yahoo Finance

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Loni...

 Acelyrin sheds pipeline, lays off 33% of staff three months after CEO departure 

 Piper Sandler bullish on Acelyrin stock, cites major catalysts on horizon By Investing.com 

 ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is 

Acelyrin drops izokibep, lays off 3rd of staff

Acelyrin eye drug heads to late-stage testing after trial win - BioPharma Dive

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen - Fierce Biotech

 Acelyrin reports FY23 EPS ($5.43), consensus ($7.40) 

Understanding risk factors associated with uveitis is key to advocating for yourself or a loved one if symptoms arise. Autoimmune or infectious conditions including rheumatoid/psoriatic arthritis, lupus and herpes zoster increase risk for uveitis. This #UveitisAwarenessMonth, learn more about other risk factors for uveitis from the Mayo Clinic. https://lnkd.in/eHv_7ki4

Acelyrin stock drops as izokibep trial fails to meet primary endpoint - MSN

Acelyrin eyes IPO boost to $400M haul to take on Lilly, ...

 ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab 

SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024 - InvestorPlace

 Acelyrin Founder Steps Down as CEO 

ACELYRIN

Business:

Drug notes:

About: